Alpine Immune Sciences, Inc , a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases.
infoAlpine Immune Sciences is a small cap stock with a total market cap of 647.00M.
infoThey trade on the NASDAQ and had their IPO 8 years and 2 months ago.
infoAlpine Immune Sciences currently employs 126 people.
infoAs of Wednesday, Aug 23 2023, Alpine Immune Sciences’s share price is $13.15.
News Relating to Alpine Immune Sciences
Zacks Investment Research
Alpine Immune (ALPN) Stock Up 19% MTD, Will the Uptick Continue?
Thursday Jun 22 2023 at 08:51
Alpine Immune has been riding on positive momentum surrounding its under-development drug program.
Zacks Investment Research
Alpine Immune Sciences, Inc. (ALPN) Soars 5.6%: Is Further Upside Left in the Stock?
Wednesday Jun 21 2023 at 02:03
Alpine Immune Sciences, Inc. (ALPN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Business Wire
Alpine Immune Sciences to Present Data from RUBY-1, a Phase 1 Study of Povetacicept, at Upcoming Scientific Congresses
Friday May 19 2023 at 16:30
SEATTLE–(BUSINESS WIRE)–Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced the Company will present data from RUBY-1, a phase 1 study of povetacicept in healthy adult volunteers, at multiple upcoming scientific congresses, including participation in a poster tour at the European Congress of Rheumatology (EULAR) and an oral presentation at the European Hemato.
Seeking Alpha
Alpine Immune: Rebuilding Itself From Scratch, But Long Way To Go Before Proof
Wednesday Mar 29 2023 at 07:37
Last year, ALPN ditched its lead program after a second patient death in a CD28 molecule, a previously notorious pathway. ALPN has started all over again, with backing from a few big pharma.
Seeking Alpha
Alpine Immune Sciences, Inc. (ALPN) Q4 2022 Earnings Call Transcript
Thursday Mar 23 2023 at 19:41
Alpine Immune Sciences, Inc. (NASDAQ:ALPN ) Q4 2022 Earnings Conference Call March 23, 2023 4:30 PM ET Company Participants Temre Johnson – SD, IR Mitchell Gold – Executive Chairman, CEO Stanford Peng – President, Head of R&D Paul Rickey – CFO Conference Call Participants Mike Ulz – Morgan Stanley Tara Bancroft – Cowen Mark Breidenbach – Oppenheimer Joe Pantginis – H.C. Wainwright Operator Welcome to the Alpine Immune Sciences Fourth Quarter 2022 Earnings Call.
Zacks Investment Research
Alpine Immune Sciences, Inc. (ALPN) Reports Q4 Loss, Lags Revenue Estimates
Thursday Mar 23 2023 at 19:03
Alpine Immune Sciences, Inc. (ALPN) delivered earnings and revenue surprises of -51.85% and 73.36%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Business Wire
Alpine Immune Sciences to Present Povetacicept (ALPN-303) Phase 1 (RUBY-1) Study Data and Clinical Pharmacokinetic & Pharmacodynamic Modeling at Upcoming Scientific Conferences
Monday Mar 20 2023 at 16:30
SEATTLE–(BUSINESS WIRE)–Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, will present posters at the American Society for Clinical Pharmacology & Therapeutics (ASCPT) Annual Meeting and at the International Society of Nephrology World Congress of Nephrology (WCN).
Business Wire
Alpine Immune Sciences to Present Povetacicept (ALPN-303) Phase 1 (RUBY-1) Study Data at the 2023 American Academy of Dermatology Annual Meeting
Thursday Mar 16 2023 at 17:30
SEATTLE–(BUSINESS WIRE)–Alpine Immune Sciences, Inc.
Business Wire
Alpine Immune Sciences to Report Fourth Quarter and Full Year 2022 Financial Results
Wednesday Mar 15 2023 at 16:30
SEATTLE–(BUSINESS WIRE)–Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the Company will release fourth quarter and full year 2022 financial results on Thursday, March 23, 2023, after the close of market. The Company will host a corresponding conference call and live webcast at 4:30 p.m. ET/1:30 p.m. PT on the same day.
Seeking Alpha
Alpine Immune Sciences, Inc. (ALPN) Q3 2022 Earnings Call Transcript
Monday Nov 14 2022 at 19:09
Alpine Immune Sciences, Inc. (NASDAQ:ALPN ) Q3 2022 Results Conference Call November 14, 2022 4:30 PM ET Company Participants Temre Johnson – SD, IR Mitchell Gold – Executive Chairman, CEO Stanford Peng – President, Head of R&D Andrew Sandler – CMO Paul Rickey – CFO Operator Welcome to the Alpine Immune Sciences Third Quarter Earnings Call. Currently all participants are in a listen-only mode.
Zacks Investment Research
Alpine Immune Sciences, Inc. (ALPN) Reports Q3 Loss, Misses Revenue Estimates
Monday Nov 14 2022 at 18:48
Alpine Immune Sciences, Inc. (ALPN) delivered earnings and revenue surprises of -320% and 59.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Business Wire
Alpine Immune Sciences to Report Third Quarter 2022 Financial Results
Monday Nov 07 2022 at 16:30
SEATTLE–(BUSINESS WIRE)–Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the company will release third quarter 2022 financial results on Monday, November 14, 2022, after the close of market.
Zacks Investment Research
Strength Seen in Alpine Immune Sciences, Inc. (ALPN): Can Its 7.5% Jump Turn into More Strength?
Friday Nov 04 2022 at 06:01
Alpine Immune Sciences, Inc. (ALPN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Zacks Investment Research
After Plunging 23.2% in 4 Weeks, Here’s Why the Trend Might Reverse for Alpine Immune Sciences, Inc. (ALPN)
Friday Oct 28 2022 at 11:18
Alpine Immune Sciences, Inc. (ALPN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Seeking Alpha
Alpine Immune Sciences: ALPN-202 May Be Dead, But The Company Isn’t
Thursday Oct 27 2022 at 10:33
The recent termination of ALPN-202 trials due to another patient’s death caused the share price to plummet. While this was anticipated, I believe that the market has overreacted due to several reasons.
Seeking Alpha
Alpine: Ramifications Of The Davoceticept Termination
Thursday Oct 27 2022 at 05:51
The second patient death prompted Alpine to terminate any future development of davoceticept. It’s prudent that Alpine stopped unfruitful developments early on to focus on lower-hanging fruits.
Zacks Investment Research
Alpine Immune Sciences, Inc. (ALPN) Moves to Buy: Rationale Behind the Upgrade
Monday Aug 15 2022 at 13:32
Alpine Immune Sciences, Inc. (ALPN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company’s earnings prospects. This might drive the stock higher in the near term.
Zacks Investment Research
Alpine Immune Sciences, Inc. (ALPN) Reports Q1 Loss, Tops Revenue Estimates
Thursday May 12 2022 at 19:34
Alpine Immune Sciences, Inc. (ALPN) delivered earnings and revenue surprises of -47.06% and 2.07%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Business Wire
Alpine Immune Sciences Announces Participation in May Investor Conferences
Tuesday May 03 2022 at 08:05
SEATTLE–(BUSINESS WIRE)–Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced that members of its management team will participate at the following investor conferences in May 2022: LifeSci Partners Immunology & Inflammation Symposium Date: Tuesday, May 10, 2022 Time: 3:00 p.m. ET/12:00 p.m. PT Event: Fireside Chat BofA Securities Healthcar
Seeking Alpha
Alpine: Rest Before Rallying Again
Monday Apr 25 2022 at 12:08
Implementing an appropriate strategy would capture the most profits. One such strategy is diversification. A promising stock for your portfolio to diversify is Alpine Immune Science. As a rising leader in immuno-oncology, Alpine has great medicines and has thus been able to secure three interesting partnerships.
Benzinga
Alpine Immune’s Davoceticept Monotherapy Reduces Tumors In Early Stage Study
Wednesday Apr 13 2022 at 10:00
Alpine Immune Sciences Inc (NASDAQ: ALPN) announced the oral presentation of results from the dose-escalation portion of NEON-1 study of davoceticept monotherapy in advanced malignancies. The data were shared at the 2022 Annual Meeting of the American Association for Cancer Research.
Zacks Investment Research
Alpine Immune Sciences, Inc. (ALPN) Reports Q4 Loss, Misses Revenue Estimates
Thursday Mar 17 2022 at 18:48
Alpine Immune Sciences, Inc. (ALPN) delivered earnings and revenue surprises of -100% and 45.18%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks Investment Research
Alpine Immune Sciences, Inc. (ALPN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Thursday Mar 10 2022 at 16:33
Alpine Immune Sciences, Inc. (ALPN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Research
Alpine (ALPN) Down on FDA Partial Clinical Hold on Cancer Study
Tuesday Mar 08 2022 at 12:47
The FDA places a partial clinical hold on Alpine’s (ALPN) NEON-2 study evaluating the combo of davoceticept plus Merck’s Keytruda for treating advanced malignancies. Shares fall.
Benzinga
Why Alpine Immune’s Shares Are Falling Today
Monday Mar 07 2022 at 12:13
The FDA has placed a partial clinical hold on Alpine Immune Sciences Inc’s (NASDAQ: ALPN) NEON-2 trial evaluating davoceticept (ALPN-202) in combination with pembrolizumab in adults with advanced malignancies. The partial clinical hold was prompted by Alpine’s report of.
Business Wire
Alpine Immune Sciences Announces Participation in March Investor Conferences
Tuesday Mar 01 2022 at 08:05
SEATTLE–(BUSINESS WIRE)–Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced that members of its management team will participate at the following investor conferences in March 2022: Cowen’s 42nd Annual Health Care Conference Date: Monday, March 7, 2022 Time: 2:50 p.m. ET/11:50 a.m. PT Event: Fireside Chat Oppenheimer 32nd Annual Healthcare Co
Business Wire
Alpine Immune Sciences Announces Participation in January Investor Conferences
Tuesday Jan 04 2022 at 16:05
SEATTLE–(BUSINESS WIRE)–Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced that members of its management team will present at the following investor conferences in January 2022: H.C. Wainwright BIOCONNECT Virtual Conference Date: Monday, January 10, 2022 Time: Available on demand beginning 7:00 a.m. ET/4:00 a.m. PT Event: Company Presentati
Business Wire
Alpine Immune Sciences to Present ALPN-303 Data at American College of Rheumatology Convergence 2021 Annual Meeting
Monday Nov 08 2021 at 08:05
SEATTLE–(BUSINESS WIRE)–Alpine Immune Sciences to Present ALPN-303 Data at American College of Rheumatology Convergence 2021 Annual Meeting
Zacks Investment Research
Alpine Immune Sciences, Inc. (ALPN) Earnings Expected to Grow: What to Know Ahead of Q3 Release
Thursday Nov 04 2021 at 16:47
Alpine Immune Sciences, Inc. (ALPN) doesn’t possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Research
3 Small Biotech Stocks in Focus on World Arthritis Day
Tuesday Oct 12 2021 at 10:58
Here we discuss three drugs or biotech companies with promising candidates in their pipeline for Arthritis indications.
Alpine Immune Sciences Bankruptcy Risk
The Altman Z-score is a formula that measures a company’s financial health and bankruptcy risk. It assigns a numerical score based on various financial ratios. The Z-score is divided into different zones. If the Z-score is above 2.99, it indicates a lower bankruptcy risk, classifying the company as ‘safe’ or ‘non-distressed’. If the score falls below 1.81, it suggests a higher risk, indicating potential financial distress or bankruptcy. The range between 1.81 and 2.99 is called the ‘gray zone’ or zone of ambiguity.
Learn more at Investopediaopen_in_new
Alpine Immune Sciences’s Altman Z-score is 3.26 which is in the safe zone. This indicates the company is financially stable and less likely to experience financial distress or bankruptcy.
Derived from SEC.GOV filing dataopen_in_new
Alpine Immune Sciences Insider Trading
Insider trading is when individuals employed by a company buy or sell its securities following legal procedures and regulations. Company executives, directors, and employees may be permitted to buy or sell shares if they follow specific rules, such as filing a Form 4 with the SEC within two business days.
Learn more at Investopediaopen_in_new
Over the last 3 months, there has been no insider trading in Alpine Immune Sciences.
Derived from SEC.GOV filing dataopen_in_new
Debt & Income Analysis
Income quality measures a company’s operating cash flow to net income ratio. It helps investors and analysts assess the sustainability of a company’s earnings. A high QIR indicates strong cash flows, while a low QIR may indicate non-operating activities driving net income.
Learn more at WallStreetPrepopen_in_new
Alpine Immune Sciences’s Income Quality of 1.06 is greater than its Industry Group of 0.69 (53.6% greater)
Alpine Immune Sciences’s Income Quality of 1.06 is greater than its Major Industry Group of 0.71 (49.3% greater)
Alpine Immune Sciences’s Income Quality of 1.06 is greater than its Sector of 0.75 (41.3% greater)
Derived from SEC.GOV filing dataopen_in_new
Current ratio measures a company’s ability to pay off short-term debt with its current assets (assets that a company expects to use up or convert to cash within a year). It represents the $ amount of current assets a company has for every $1 of short-term debt. A high current ratio above 1.0 indicates that a company can meet its short-term obligations, while a low current ratio below 1.0 suggests difficulty.
Learn more at Investopediaopen_in_new
Alpine Immune Sciences’s Current Ratio of 3.88 is lower than its Industry Group of 4.76 (-18.5% lower)
Alpine Immune Sciences’s Current Ratio of 3.88 is lower than its Major Industry Group of 4.32 (-10.2% lower)
Alpine Immune Sciences’s Current Ratio of 3.88 is greater than its Sector of 2.6 (49.2% greater)
Derived from SEC.GOV filing dataopen_in_new
Value Analysis
PE ratio (price-to-earnings), measures a company’s stock price relative to its earnings per share. It helps investors evaluate whether its stock is overvalued or undervalued. A higher PE ratio indicates that investors are willing to pay more for a company’s earnings, while a lower PE ratio (above zero) suggests the company could be undervalued.
Learn more at Investopediaopen_in_new
Cannot compare a negative PE Ratio (-11.61 & -1.27)
Cannot compare a negative PE Ratio (-11.61 & -1.1)
Cannot compare a negative PE Ratio (-11.61 & -0.4)
Derived from SEC.GOV filing dataopen_in_new
The PB ratio (price-to-book), measures a company’s stock price relative to its book value (net value of a company’s assets reported on its balance sheet, after subtracting debt) per share. It is used to evaluate a company’s valuation, with a lower PB ratio (above zero) indicating a lower valuation and a higher PB ratio suggesting overvaluation.
Learn more at Investopediaopen_in_new
Alpine Immune Sciences’s PB Ratio of 3.82 is greater than its Industry Group of 1.34 (185.1% greater)
Alpine Immune Sciences’s PB Ratio of 3.82 is greater than its Major Industry Group of 1.4 (172.9% greater)
Alpine Immune Sciences’s PB Ratio of 3.82 is greater than its Sector of 1.62 (135.8% greater)
Derived from SEC.GOV filing dataopen_in_new
Efficiency Analysis
ROE (Return on Equity), is a financial ratio that measures a company’s profitability relative to its shareholders’ equity (the amount of value in a company that belongs to the people who own shares). It indicates how efficiently a company generates profits per unit of equity invested. A high ROE suggests effective use of equity, while a low ROE indicates inefficiency.
Learn more at Investopediaopen_in_new
Alpine Immune Sciences’s ROE of -0.33 is greater than its Industry Group of -0.44 (25.0% greater)
Alpine Immune Sciences’s ROE of -0.33 is greater than its Major Industry Group of -0.38 (13.2% greater)
Alpine Immune Sciences’s ROE of -0.33 is lower than its Sector of -0.03 (-1000.0% lower)
Derived from SEC.GOV filing dataopen_in_new
ROCE (Return on Capital Employed), is a financial ratio that measures a company’s profitability relative to the amount of capital invested in its operations. It indicates how well a company is generating profits from its capital investments. A high ROCE suggests effective use of capital, while a low ROCE indicates inefficiency.
Learn more at Investopediaopen_in_new
Alpine Immune Sciences’s ROCE of -0.33 is greater than its Industry Group of -0.42 (21.4% greater)
Alpine Immune Sciences’s ROCE of -0.33 is greater than its Major Industry Group of -0.37 (10.8% greater)
Alpine Immune Sciences’s ROCE of -0.33 is lower than its Sector of -0.04 (-725.0% lower)
Derived from SEC.GOV filing dataopen_in_new